Recent findings from a large UK Biobank analysis published in the journal Alzheimer’s & Dementia indicate that hormone replacement therapy use is associated with a modest 10% reduction in all-cause dementia risk among postmenopausal women, though the effect varies significantly depending on menopause type, estrogen exposure duration, and the timing of treatment initiation.
UK Biobank Study Findings on HRT and Dementia Risk
The study analyzed data from 183,450 postmenopausal women in the UK Biobank over a mean follow-up of 13.3 years, tracking 3,948 diagnosed dementia cases across more than 2.43 million person-years. According to the research, overall hormone replacement therapy use linked to a 10% decrease in all-cause dementia risk. When breaking down the data by subtypes, investigators noted a reduction specifically tied to Alzheimer’s dementia risk, while finding no statistically significant association with non-Alzheimer’s dementia overall.
However, the protective association shifted dramatically when researchers looked at specific biological subgroups. Women who experienced surgical menopause—defined as the removal of both ovaries or a hysterectomy—saw a 26% lower risk of dementia when using hormone therapy. By comparison, women experiencing natural menopause showed no statistically significant risk reduction overall.
Surgical Versus Natural Menopause and Estrogen Exposure
The distinction between surgical and natural menopause highlights how different physiological pathways respond to treatment. According to the study, women with surgical menopause who used hormone replacement therapy experienced a 21% reduction in non-Alzheimer’s dementia risk and a 32% reduction in Alzheimer’s dementia risk. Researchers also evaluated lifetime endogenous estrogen exposure, measured by the time span between menarche and natural or surgical menopause. Women with less than 37 years of natural estrogen exposure experienced a 16% lower risk of all-cause dementia and a 19% lower risk of Alzheimer’s dementia.
These findings contrast with a separate systematic review led by Melissa Melville, a PhD candidate and aging researcher at University College London, which analyzed 10 previous studies encompassing over 1 million participants. According to Melville’s review, researchers found no evidence that hormone therapy either increased or decreased dementia risk overall. Melville noted that available evidence remains limited and largely observational, adding that decisions regarding treatment should rely on symptom burden rather than dementia prevention.
Pro Tip: Understanding Your Menopause Type
If you’ve undergone surgical menopause, discuss your specific hormone history and symptom management plan with your doctor, as treatment responses can differ significantly from natural menopause transitions.
Timing of HRT Initiation and the Window of Opportunity
The timing of treatment initiation played a critical role in the UK Biobank findings. Initiating hormone replacement therapy between the ages of 46 and 56 yielded a reduced risk of dementia, whereas starting after age 56 did not show the same benefit. For women with natural menopause, an 18% risk reduction appeared only when treatment started in the latter half of that window, specifically between ages 51 and 56.
Conversely, women with surgical menopause saw progressively larger risk reductions with later initiation within the study window. Treatment started before age 46 reduced risk by 15%, while initiation at ages 46–50 and 51–56 lowered risk by 31% and 43%, respectively. Dr. Manisha Parulekar, director of the Division of Geriatrics at Hackensack University Medical Center, described her reaction to the findings as cautious acknowledgement, emphasizing the need to carefully weigh individual health history.
Genetic Factors and APOE ε4 Status
Researchers also investigated the role of the APOE ε4 gene variant, a major genetic risk factor for dementia. Among APOE ε4 carriers, hormone replacement therapy use showed a 13% lower risk of all-cause dementia, though the formal interaction between treatment and gene status was not statistically significant. When combined with surgical menopause, treatment was associated with a 28% lower dementia risk in APOE ε4-positive women and a 20% lower risk in APOE ε4-negative women.
Frequently Asked Questions
Does HRT always reduce dementia risk?
No. While the UK Biobank study found a modest 10% reduction in risk overall, other broad reviews, such as the University College London meta-analysis, found no evidence that hormone therapy alters dementia risk in either direction.
How does surgical menopause change HRT outcomes?
The UK Biobank data showed that women with surgical menopause experienced a 26% lower risk of dementia when using hormone therapy, compared to no statistically significant overall association in women with natural menopause.
Does the age at which treatment starts matter?
Yes. The UK Biobank analysis found risk reductions when treatment began between ages 46 and 56, with different response patterns observed depending on whether the menopause was natural or surgical.
Stay Informed on Women’s Health Research
Navigating the complex findings surrounding midlife treatments requires up-to-date, evidence-based reporting. Explore our archive for more breaking analyses on aging, neurology, and clinical research. Share your thoughts in the comments below, or subscribe to our newsletter to receive the latest scientific updates directly in your inbox.